SCHEMBL6477136

SCHEMBL6477136

COC(=O)C(=Cc1ccc(OCCn2c(=O)sc3ccccc32)cc1)C(=O)O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.63
NPC1 O15118 6/20 0.63
SMN1; SMN2 Q16637 6/20 0.63
LMNA P02545 1/20 0.63
TSHR P16473 5/20 0.61
ALDH1A1 P00352 3/20 0.61
MAPK1 P28482 3/20 0.61
L3MBTL1 Q9Y468 7/20 0.60
TP53 P04637 1/20 0.60
CYP3A4 P08684 2/20 0.55
CYP2D6 P10635 2/20 0.55
CYP2C19 P33261 2/20 0.55
CYP1A2 P05177 1/20 0.55
CYP2C9 P11712 1/20 0.55
TDP1 Q9NUW8 3/20 0.53
HPGD P15428 1/20 0.53
GAA P10253 1/20 0.52
PPARG P37231 1/20 0.48
HTT P42858 1/20 0.46
MAPT P10636 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6477124 0.95 RAB9A (0.67) RAB9ANPC1SMN1; SMN2LMNATSHR
SCHEMBL6487303 0.92 RAB9A (0.70) RAB9ANPC1SMN1; SMN2LMNATSHR
SCHEMBL6476493 0.89 RAB9A (0.59) RAB9ANPC1SMN1; SMN2LMNATSHR
SCHEMBL6476495 0.89 RAB9A (0.59) RAB9ANPC1SMN1; SMN2LMNATSHR
SCHEMBL7019578 0.87 RAB9A (0.70) RAB9ANPC1SMN1; SMN2LMNATSHR
SCHEMBL6478309 0.85 RAB9A (0.64) RAB9ANPC1SMN1; SMN2LMNATSHR
SCHEMBL6487134 0.83 PPARG (0.68) RAB9ANPC1SMN1; SMN2LMNATSHR
SCHEMBL6477610 0.80 L3MBTL1 (0.65) RAB9ANPC1SMN1; SMN2LMNATSHR
SCHEMBL6476836 0.80 PPARA (0.56) RAB9ANPC1SMN1; SMN2LMNATSHR
SCHEMBL6476834 0.80 PPARA (0.56) RAB9ANPC1SMN1; SMN2LMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6919362-B2 Heterocyclic derivatives, preparation method and pharmaceutical compositions containing same LES LABORATOIRES SERVIER (FR) 2005-07-19 US disclosed
US-20030040533-A1 Novel heterocyclic derivatives, preparation method and pharmaceutical compositions containing same LES LABORATOIRES SERVIER (FR) 2003-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030040533-A1 Novel heterocyclic derivatives, preparation method and pharmaceutical compositions containing same CYP2F1, CYP11B2, CYP4B1 RAB9A 3361/4885NPC1 1716/4885SMN1; SMN2 1823/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.